Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668950 · ClinicalTrials.gov registry record · Phase 3
Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)
A Phase 3 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 670
- Enrollment target
NCT04668950: Completed Phase 3 study, sponsored by Washington University School of Medicine.
NCT04668950 is a Phase 3 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 670 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04668950, a Phase 3 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 670 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsive disorder. The use of fluvoxamine for the treatment of COVID-19 is considered investigational, which means the US Food and Drug Administration has not approved it for this use. This study is fully-remote, which means that there is no face-to-face contact; study materials including study drug will be shipped to participants' houses. People around the United States and Canada can participate.
Primary Outcome
Defined as the number of participants who experienced the following: both of the following: 1)Presence of dyspnea and/or hospitalization for shortness of breath or pneumonia, 2)) decrease in O2 saturation (\<92% on room air) and/or supplemental oxygen requirement to keep O2 saturation ≥92%).
Interventions
- DRUG Placebo
- DRUG Fluvoxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2021-09-28 |
| Phase | Phase 3 |
What the finished NCT04668950 record still lists
NCT04668950 is an interventional study that assigns participants to a tested intervention. The registered 670 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04668950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04668950 about?
NCT04668950 is a clinical study titled "Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)". The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsi...
What is the current status of trial NCT04668950?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 670 participants. The study started on 2020-12-22. Estimated completion is 2021-09-28.
What interventions are being tested in trial NCT04668950?
The interventions under investigation include: Placebo (DRUG), Fluvoxamine (DRUG).
Who is sponsoring clinical trial NCT04668950?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04668950's enrollment target sits among peer trials
670 546th of 2000 higher than 1,454 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02984761 · 670 participants · NA
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- NCT05727904 · 670 participants · Phase 3
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- NCT06223867 · 670 participants · NA
Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part A
- NCT07184944 · 671 participants · Phase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI